Literature DB >> 29085517

FHIT promoter DNA methylation and expression analysis in childhood acute lymphoblastic leukemia.

Gholamreza Bahari1,2, Mohammad Hashemi1,2, Majid Naderi3, Simin Sadeghi-Bojd3, Mohsen Taheri4.   

Abstract

Fragile histidine triad (FHIT) is a tumor suppressor gene, which is involved in several malignancies. Epigenetic alterations in FHIT have been hypothesized to contribute to tumorigenesis. The present study aimed to examine DNA promoter methylation and gene expression levels of FHIT in childhood acute lymphoblastic leukemia (ALL), in a sample of Iranian patients. The promoter methylation status of FHIT was analyzed in 100 patients diagnosed with ALL and 120 healthy control patients. mRNA expression levels were assessed in 30 new cases of ALL compared with 32 healthy controls. Hypermethylation of the FHIT promoter was significantly more frequent in patients with ALL than in healthy controls (OR=3.83, 95% CI=1.51-9.75, P=0.007). Furthermore, FHIT mRNA expression levels were significantly reduced in childhood ALL patients compared with healthy controls (P=0.032). The results of the present study revealed that dysregulation of the FHIT gene may contribute to the pathogenesis of childhood ALL. Future studies investigating a larger sample population with greater ethnic diversity would be beneficial, to confirm the results from the present study.

Entities:  

Keywords:  fragile histidine triad; gene expression; methylation

Year:  2017        PMID: 29085517      PMCID: PMC5649531          DOI: 10.3892/ol.2017.6796

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  45 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells.

Authors:  H Ishii; K R Dumon; A Vecchione; F Trapasso; K Mimori; H Alder; M Mori; G Sozzi; R Baffa; K Huebner; C M Croce
Journal:  Cancer Res       Date:  2001-02-15       Impact factor: 12.701

3.  Methylation status of the FHIT gene in the transformed human mesenchymal F6 stem cell line.

Authors:  Xue-Jing Xu; Shuo Gao; Mei Wang; Hui Qian; Guang-Yu Gu; Kui Zhang; Wen-Rong Xu
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

4.  Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer.

Authors:  Rabeah Abbas Al-Temaimi; Sindhu Jacob; Waleed Al-Ali; Diana Ann Thomas; Fahd Al-Mulla
Journal:  J Histochem Cytochem       Date:  2013-06-24       Impact factor: 2.479

5.  Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma.

Authors:  De-Tao Yin; Lin Wang; Jianrui Sun; Fengyan Yin; Qingtao Yan; Rulong Shen; Gang He; Jian-Xin Gao
Journal:  Int J Clin Exp Pathol       Date:  2010-05-25

6.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.

Authors:  Luca Roz; Marcella Gramegna; Hideshi Ishii; Carlo M Croce; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

7.  Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in breast cancer cell lines.

Authors:  Cinzia Sevignani; George A Calin; Rossano Cesari; Manuela Sarti; Hideshi Ishii; Sai Yendamuri; Andrea Vecchione; Francesco Trapasso; Carlo M Croce
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

8.  Frequent aberration of FHIT gene expression in acute leukemias.

Authors:  T Iwai; S Yokota; M Nakao; N Nakazawa; M Taniwaki; T Kimura; Y Sonoda; H Kaneko; T Okuda; H Azuma; T Oka; T Takeda; A Watanabe; A Kikuta; K Asami; I Sekine; T Matsushita; T Tsuchiya; J Mimaya; S Koizumi; S Ohta; M Miyake; Y Takaue; A Iwai; T Fujimoto
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

9.  DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia.

Authors:  Shuchi Agrawal; Matthias Unterberg; Steffen Koschmieder; Udo zur Stadt; Uta Brunnberg; Walter Verbeek; Thomas Büchner; Wolfgang E Berdel; Hubert Serve; Carsten Müller-Tidow
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 10.  The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.

Authors:  Xiaoyu Wu; Guannan Wu; Xuequan Yao; Gang Hou; Feng Jiang
Journal:  Drug Des Devel Ther       Date:  2016-02-15       Impact factor: 4.162

View more
  2 in total

1.  FHIT as a biomarker for early screening of adult T-cell leukemia.

Authors:  Marcia Bellon; Christophe Nicot
Journal:  J Cancer Biol       Date:  2021

Review 2.  Genetics of blood malignancies among Iranian population: an overview.

Authors:  Majid Ghayour-Mobarhan; Amir Sadra Zangouei; Seyed Mohammad Hosseinirad; Majid Mojarrad; Meysam Moghbeli
Journal:  Diagn Pathol       Date:  2020-05-06       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.